The mitochondrial theory of aging proposes that mitochondrial DNA (mtDNA) accumulates mutations with age, and that these mutations contribute to physiological decline in aging and degenerative diseases. Although a great deal of indirect evidence supports this hypothesis, the aggregate burden of mtDNA mutations, particularly point mutations, has not been systematically quantified in aging or neurodegenerative disorders. Therefore, we directly assessed the aggregate burden of brain mtDNA point mutations in 17 subjects with Alzheimer's disease (AD), 10 elderly control subjects and 14 younger control subjects, using a PCR-cloningsequencing strategy. We found that brain mtDNA from elderly subjects had a higher aggregate burden of mutations than brain mtDNA from younger subjects. The average aggregate mutational burden in elderly subjects was 2 × 10 -4 mutations/bp. The bulk of these mutations were individually rare point mutations, 60% of which changed an amino acid. Control experiments ensure that these results were not due to artifacts arising from PCR error, mistaken identification of nuclear pseudogenes or ex vivo oxidation. Cytochrome oxidase activity correlated negatively with increasing mutational burden. These findings significantly bolster the mitochondrial theory of aging.
INTRODUCTION
The mitochondrial theory of aging proposes that accumulation of mutations in mitochondrial DNA (mtDNA) and consequent mitochondrial dysfunction are major contributors to aging and age-related neurodegenerative diseases such as Alzheimer's disease (AD) (1) . Several indirect lines of evidence support this hypothesis. Potentially mutagenic lesions (2) such as 8-hydroxy-2′-deoxyguanosine (OH 8 dG) accumulate in mtDNA in aging (3) and AD (4) . Mitochondrial electron transport chain activities decrease in aging (5) and in AD (6) (7) (8) , and these electron transport defects can be reproduced in vitro by expressing mtDNA from patients in cell lines (9) (10) (11) . Decline in mitochondrial function with aging has therefore been attributed to mutations in mtDNA.
However, specific mtDNA mutations responsible for the defects seen in aging and AD have yet to be identified. Large mtDNA deletions have consistently been reported to increase with age (12) (13) (14) (15) (16) , but the absolute level of any one particular mutation is generally low (<1%), below the threshold of ∼50% (17) thought necessary to cause dysfunction. A variety of individual point mutations have been reported to increase with age (18) and AD (19) (20) (21) (22) (23) , but have not been consistently reproduced by other laboratories (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) or are single unconfirmed reports (36, 37) . Thus, single individual mutations appear unlikely to account for mitochondrial decline in aging. Therefore, it has been proposed that it may be the aggregate burden of multiple mutations, each of which may be individually rare, that impairs mitochondrial function (38) .
However, surprisingly, the aggregate burden of mtDNA mutations, particularly point mutations, has not been systematically quantified in aging or neurodegenerative disorders. Initial studies of point mutations used allele-specific PCR to show that levels of single specific mutations, such as the A3243G MELAS mutation, increase with aging (39, 40) , although never reaching more than a very small fraction (<0.1%) of the total mtDNA. However, these types of studies assessed only the specific mutations for which the primers were designed, not the aggregate burden of point mutations.
Other studies have used denaturing gradient electrophoresis to separate molecules with point mutations as a group, based on alterations in melting temperature. However, early studies using this technique examined only small numbers of elderly subjects (41, 42) . A more extensive study suggested the agerelated accumulation of several specific mutations in fibroblasts from elderly subjects (43) , but this was not seen in brain (44, 45) . Finally, aggregate point mutational burden has also been examined by cloning and sequencing. Using this approach, one report suggested that striatum from subjects with Parkinson's disease had a significant increase in the aggregate burden of point mutations in ND1 (46) . However, only three subjects were studied. Thus, various limitations in prior studies prevent firm conclusions about whether the *To whom correspondence should be addressed. Tel: +1 212 746 4573; Fax: +1 212 746 8276; Email: mtl2002@med.cornell.edu aggregate burden of mtDNA point mutations increases in aging or neurodegenerative diseases.
Therefore, we directly assessed the aggregate burden of mtDNA point mutations in a 1197 bp fragment of cytochrome oxidase (CO) in aging and AD brain, using a PCR-cloningsequencing strategy.
RESULTS

Brain mtDNA from AD and elderly control subjects contains a higher aggregate burden of individually rare point mutations than young subjects
Our cloning-sequencing strategy ( Fig. 1 ) revealed numerous mutations, defined as discrepancies with the Cambridge reference sequence, in the CO1 gene of brain mtDNA from both AD and elderly control subjects. Out of 331 545 bp (500 clones) examined in 28 AD samples, 99 mutations were found, and out of 354 318 bp (569 clones) examined in 20 elderly control samples, 95 mutations were found. Without correction for PCR error, the mean aggregate mutational burden was 2.96 ± 2.02 × 10 -4 mutations/bp (mean ± SD) in AD subjects, and 2.89 ± 1.35 × 10 -4 mutations/bp in elderly controls (Fig. 2) . Subtracting the 1.18 ± 0.34 × 10 -4 mutations/bp attributable to PCR error (see below), the mean aggregate mutational burden in all elderly subjects combined was 1.75 ± 1.59 × 10 -4 mutations/bp.
To determine whether these mutations accumulate with aging, we also examined brain mtDNA from younger control subjects using the same cloning sequencing strategy. Out of 925 732 bp (1512 clones) examined in 19 young control samples, 114 mutations were found. Without correction for PCR error, the average aggregate mutational burden in young subjects was 1.21 ± 0.57 × 10 -4 mutations/bp. This is no different from the mutation level attributable to PCR error, and is statistically less than the uncorrected burden present in AD subjects (P = 0.0014) or elderly controls (P = 0.0056) (ANOVA with Scheffe's test; Fig. 2A ). Detailed correlation also demonstrates that aggregate mutational burden in brain mtDNA increases with age (P = 0.0004; Fig. 2B ).
The entire region examined was susceptible to mutations (Fig. 3A) . Although some intervals appeared to have a higher frequency of mutations, the vast majority of mutations in AD and elderly control subjects were individually rare. Of the 194 mutations found in all 1069 clones taken from AD and elderly control subjects combined, 133 mutations were found in only one clone, 27 were found in two clones, one was found in three clones and one was found in four clones. Thus, the majority of mutations were found in only one individual, in only one brain region, and in at most one or two clones of the Figure 1 . Strategy for identifying low-frequency mutations. Tissue homogenates are enriched for mitochondria prior to DNA extraction, to minimize contamination with nuclear pseudogenes. A segment of interest (CO1) is PCR amplified to produce amounts and sizes of DNA appropriate for cloning into bacteria. A high-fidelity polymerase is used to minimize PCR error. Mutations on individual molecules are separated by cloning and individually amplified prior to sequencing. Direct sequencing of the bulk PCR product without cloning will not detect low-frequency mutations.
24-96 clones from that region. In contrast, there were only six examples of homoplasmic mutations, and only one instance of a high-level (70%) heteroplasmic mutation, found in most clones from all brain regions in a given subject. Five of the six homoplasmic mutations (C6518T, C6528T, T6221C, C6371T, G6026A) were silent. The remaining homoplasmic mutation (T6345C→F148L) and the high-burden heteroplasmic mutation (G6150A→V83I) did change amino acids, but they were both found in control subjects and unlikely to be of pathogenic significance. Although we cannot exclude the possibility that these homoplasmic or high-level heteroplasmic mutations were acquired, it is much more likely that they were inherited than that the same acquired mutation should independently arise and become homoplasmic in two separate brain areas. Thus, only the low-level heteroplasmic mutations were further characterized.
Nearly all of the mutations in both AD subjects and elderly controls were point mutations. The vast majority (88%) of the mutations were transitions, with a lower frequency (10%) of transversions and occasional deletions (2%), in close agreement with the types of point substitutions found in the MITOMAP database (Fig. 3B) . The point mutations were approximately equally distributed among the three nucleotide positions within a codon in both AD and elderly controls. In contrast, the 497 protein gene point substitutions listed in the MITOMAP database show a clear preference for the codon third position (P < 0.0001, χ 2 test) (Fig. 3C) . In both AD and elderly control brains, none of the third position mutations changed an amino acid, all of the second position mutations changed an amino acid, and almost all of the first position mutations changed an amino acid. The net result is that ∼60% of the point mutations would result in an amino acid change (55% for AD, 58% for aged controls), more than the 43% of MITOMAP protein gene point substitutions that change an amino acid (P = 0.006, Fisher exact test).
For both AD and elderly control subjects, we also determined whether the aggregate mtDNA mutational burden systematically differed in different cortical areas. For 11 AD and 10 elderly control subjects, samples were available both from a polymodal cortical area, generally found to be hypometabolic in AD when imaged by positron-emission tomography (PET), and from primary occipital cortex, generally normal on PET imaging (47) . The average difference in aggregate mutational burden between occipital and polymodal cortices (Fig. 3D ) was 0.20 ± 3.68 × 10 -4 mutations/bp for AD subjects and 0.11 ± 2.05 × 10 -4 mutations/bp for elderly control subjects, neither significantly different from zero (P > 0.8, two-tailed t-test). Thus, no systematic difference was detected in aggregate mutational burden between the cortical areas examined.
Finally, no difference in average aggregate mutational burden was detected between AD and elderly control subjects (P = 0.89, two-tailed t-test), despite 80% power to detect an increase of 1.2 × 10 -4 mutations/bp or greater over the elderly control mean of 2.89 × 10 -4 mutations/bp. There was also no difference detected between brain mtDNA from AD and elderly Figure 2 . Aggregate mutational burden in brain mtDNA from AD subjects, elderly control subjects and young control subjects. (A) The aggregate mutational burden (number of mutations found in multiple clones, divided by the total number of base pairs sequenced) is shown for each of 28 samples from AD subjects, 20 samples from elderly control subjects and 19 samples from young control subjects. Also shown is the mutational burden attributable to PCR error (n = 12 trials). For each group, the means ± SD are shown offset to the right. AD, greater than the aggregate mutational burden in younger subjects (P = 0.0014) and the mutational burden attributable to PCR error (P = 0.0069). OLD CON, greater than the aggregate mutational burden in younger subjects (P = 0.0056) and the mutational burden attributable to PCR error (P = 0.0171) (ANOVA with Scheffe's test). (B) Mutational burden versus age. Including all samples from all subjects, there is a positive correlation between mutational burden and age (solid line, slope = 0.024, different from 0 at P = 0.0004; dotted lines, the 95% confidence interval on the slope).
control subjects in types of point substitutions, distribution within the three codon positions or frequency of amino acid change.
The mutations detected are unlikely to be due solely to PCR error One major potential source of error in identifying mitochondrial mutations is to mistake PCR polymerase errors for mutations present in the original mtDNA. Our mutation identification strategy involved two PCR steps: (i) a pre-cloning step, to produce amounts and sizes of DNA appropriate for cloning and to eliminate extraneous sequences; and (ii) a post-cloning step, to recover the insert from a single colony and amplify it to a level amenable to sequencing. Errors occurring in the pre-cloning PCR are of the most concern because individual molecules of the pre-cloning PCR product are separated and selected by the subsequent cloning procedure. Therefore, errors in individual molecules are detected. In contrast, the post-cloning PCR product is sequenced as a bulk mixture, without selection of individual molecules, and an individual error must be present at some threshold fraction of molecules in the mixture (∼40% by mixing studies; data not shown) to be distinguishable from noise. Given at least 1000 starting copies of the template in a bacterial colony, even a polymerase with an error rate as high as 1 × 10 -4 /bp will not make the same error in the same location in 40% of molecules. Thus, errors in the post-cloning PCR step will not introduce a measurable artifact (Fig. 4A) .
For the pre-cloning PCR, we used a high-fidelity polymerase with proofreading activity (Expand High Fidelity Polymerase, There were 11 AD subjects and 10 elderly control subjects from whom both an occipital and a polymodal cortical sample were available. For each subject, the difference in aggregate mutational burden between occipital and polymodal cortex is shown. For each group, the means ± SD are shown offset to the right. For both AD and elderly control subjects, the mean difference in aggregate mutational burden between cortical areas was zero, indicating no systematic variation in aggregate mutational burden between the brain regions examined.
Roche Molecular Biochemicals, Indianapolis, IN), and the error rate specified by the manufacturer is 8.5 × 10 -6 /base. However, the overall PCR error after multiple cycles is higher than this, because old errors are propagated from earlier cycles and new ones accumulate with each cycle. Given the polymerase error rate, the length of the strand to be amplified (1197 bases), and the number of PCR cycles (27) , a simple mathematical model can be used to calculate the expected fraction of PCR products with zero, one, two, three or four errors, giving 87.2, 11.9, 0.8, 0.04 and 0.002%, respectively (Materials and Methods). Therefore, if one sequenced 100 individual clones (molecules) from this PCR product, the expected number of errors would be (0 × 87.2) + (1 × 11.9) + (2 × 0.8) + (3 × 0.04) + (4 × 0.002) = 13.628, out of a total 119 700 bases examined. Therefore, the calculated overall error rate is 1.14 × 10 -4 errors/bp.
We also experimentally measured the overall pre-cloning PCR error rate, by using a single bacterial colony instead of brain mtDNA as a template for pre-cloning PCR. Individual molecules of this PCR product were separated by means of a second cloning reaction, and 48 clones were sequenced (Fig. 4B) . The entire process of examining multiple clones of a PCR product from a single clone was repeated multiple times. It should be noted that the 'effective' PCR error rate measured by this scheme actually includes bacterial replication error as well as PCR error. However, this scheme is identical to that used for brain mtDNA, and the effective PCR error rate is therefore applicable without modification. The effective PCR error measured was 1.18 ± 0.34 × 10 -4 errors/bp (n = 12 trials, 340 699 total bases examined), in close agreement with the predicted rate calculated above. The average aggregate mtDNA burden of ∼3.0 × 10 -4 mutations/bp in both AD and elderly control brain is therefore 2.5 times the mutational burden effectively attributable to PCR error, and is unlikely (P < 0.017) to be due solely to that error (Fig. 2) . Furthermore, the effective PCR error is not expected to be different in brain mtDNA from young versus elderly subjects, and therefore cannot account for the difference in aggregate burden between young and elderly subjects.
The mutations detected are unlikely to be due to a pseudogene artifact A second major potential source of error in identifying mitochondrial mutations is to mistake nucleus-embedded mtDNA pseudogenes for bona fide mtDNA. Evolutionary variants in the nuclear pseudogenes not present in the mtDNA could give the appearance of heteroplasmy (33) (34) (35) . Therefore, extensive precautions were taken to avoid contamination with nuclear pseudogenes. First, mitochondria were crudely separated from nuclei by differential centrifugation followed by an additional gradient centrifugation. Secondly, DNA was isolated by standard SDS/proteinase K digestion followed by organic extraction, instead of the boiling technique (23) previously shown to enrich for pseudogenes (33) . Thirdly, the degree of nuclear DNA contamination was assessed, using PCR amplification of a histone sequence as a marker of nuclear DNA. Putative mtDNA samples were used only if the histone PCR product was faint or absent compared to the CO1 PCR product (Fig. 5, lanes 2 and 6) . Fourthly, the PCR primers for CO1 were chosen because they fail to give a visible product from 143B osteosarcoma-derived ρ 0 cells (Fig. 5, lane 7) , despite the presence of abundant nuclear DNA (Fig. 5, lane 3) . Thus, even in the presence of significant nuclear DNA contamination, the choice of primers ensures that pseudogenes would not contribute to the PCR product used for subsequent cloning and sequencing.
Finally, even with these precautions, the mutations found were still checked to see if they were potentially pseudogene 'mutations'. Using different PCR primers from ours, Hirano et al. (33) recovered a CO1 pseudogene from 143B ρ 0 cells, and Wallace et al. (34) a CO1 pseudogene from WAL2A-EB2 ρ 0 cells. These pseudogenes differed from the Cambridge reference sequence at 14 sites between 5951 and 6560, and we compared these 'mutations' to the mutations found in brain. Of the 159 distinct mutations we found between nucleotides 5951 and 6560, five were also found in ρ 0 cells. This represents only 3% of the 159 mutations distinct mutations found in brain, and is well within the 95% confidence interval (4 ± 3) expected by chance alone. Furthermore, a clone of a pseudogene fragment should have multiple mutations. The 143B pseudogene had 12 mutations between nucleotides 5951 and 6560, and the WAL2A-EB2 pseudogene had a slightly different 12. In contrast, of the five clones we found bearing a potential pseudogene mutation, none bore a second potential pseudogene mutation. Finally, if pseudogenes were conserved and contributed significantly to the mutations being detected, the same mutations should have appeared abundantly and repeatedly in multiple individuals. When Davis et al. (23) inadvertently examined CO1 pseudogenes, they found three linked putative 'mutations' at levels of 20.3% or more in 60% of their AD cases and 20% of their controls. In contrast, of our five potential pseudogene mutations, none was present on more than one clone out of all clones from all subjects. Thus, although it is impossible to exclude pseudogene contamination absolutely, we believe that it is minimal because of extensive precautions.
The mutations detected are unlikely to be due to ex vivo oxidation
A third potential source of error in identifying mitochondrial mutations is to mistake DNA modifications due to ex vivo oxidation for mutations present in vivo. In particular, phenol, used for DNA extraction, can reduce metal ions, which can then participate in Fenton chemistry, generate hydroxyl radicals, and oxidize DNA (48) . Phenol extraction can increase the level of OH 8 dG in DNA 20-fold, especially if the sample is subsequently exposed to oxygen (49) . Conversely, recent phenol-free DNA isolation methods, which use the chaotropic salt NaI to remove proteins by precipitation (50) and which include metal ion chelators, decrease the level of OH 8 dG 10-100-fold (51) (52) (53) . Because OH 8 dG can pair incorrectly with adenine, it is possible that ex vivo oxidation might result in induction of point mutations during the pre-cloning PCR reaction. Therefore, we tested the effect of ex vivo oxidation on the level of mutations detected by our cloning-sequencing strategy. Phenol extracted buffy coat DNA from a young control subject (110 µg in 16 mM sodium acetate, pH 5.2) was exposed for 1 h (25°C) to either Fenton chemistry (25 µM FeSO 4 + 250 mM H 2 O 2 ) or buffer in a total volume of 50 µl. The DNA was then ethanol precipitated, reconstituted in TE buffer, and used for PCR, cloning and sequencing as described above. These are harsh oxidant conditions which increase the level of OH 8 dG 15-fold in commercial calf-thymus DNA (54) , and more prolonged incubation does not lead to further increase. However, there was only a slight and statistically non-significant increase in the mutational burden of Fenton-oxidized DNA (1.36 ± 1.25 × 10 -4 mutations/bp, n = 4 trials, 46 360 total bases) compared to the control DNA (0.84 ± 0.63 × 10 -4 mutations/bp, n = 5 trials, 62 971 total bases). In fact, these levels are indistinguishable from the PCR-induced noise measured above, in which no phenol was used or oxidant stress applied.
The mutations detected are associated with decreased CO activity
To determine if there was a functional correlate for the mtDNA mutations found in CO, enzymatic activity was assayed in 25 of the original 67 samples for which there was sufficient residual frozen brain tissue to isolate additional mitochondria. CO activity was measured, and values were normalized to citrate synthase (CS) to control for variable concentrations of mitochondria between preparations. There were statistically significant negative correlations of CO activity (normalized to CS) with increasing age (P = 0.0077; Fig. 6A ) and with increasing mitochondrial mutational burden (P = 0.0256; Fig. 6B ). The mean CO/CS ratio was 2.20 ± 0.26 (n = 9) in young control subjects, 1.73 ± 0.34 (n = 6) in elderly control subjects and 1.82 ± 0.33 (n = 10) in AD subjects. The mean for young control subjects was significantly different from that of elderly control subjects (P = 0.0316) and AD subjects (P = 0.0480) (ANOVA with Scheffe's test). The mean for elderly subjects is ∼20% decreased from the mean for young subjects.
DISCUSSION
To our knowledge, this work is the first systematic study quantifying the aggregate burden of mtDNA point mutations in large numbers of subjects, including both normal subjects and those with a neurodegenerative disease. Uncorrected for PCR error, the mean aggregate burden of low-frequency point mutations in CO1 from brain mtDNA was ∼3 × 10 -4 /bp for both elderly control subjects and subjects with AD. This is twice the level that was found in younger controls, strongly suggesting that these point mutations accumulate or are acquired with aging. Control studies demonstrate that this level of aggregate mutational burden in elderly subjects is not due to PCR error, nucleus-embedded mitochondrial pseudogenes or ex vivo oxidation. The mutational burden due to PCR error was ∼1 × 10 -4 /bp, with experimental determinations and mathematical modeling in close agreement. Correcting for this error, the aggregate burden of point mutations in CO1 is ∼2 × 10 -4 /bp for elderly subjects. This estimate is also in agreement with work based on an even higher fidelity polymerase than that used in the present study (D.K. Simon . It should be noted that although the aggregate burden of point mutations in young controls is statistically less than the burden in elderly subjects, it is not statistically different from PCR noise, and therefore cannot be accurately assessed with the current polymerase. An estimated aggregate point mutation level of 2 × 10 -4 /bp is surprisingly high compared with the few previous studies of aggregate point mutation levels in mitochondria. Using a scheme involving several cycles of denaturing gradient electrophoresis, Khrapko et al. (42) found a point mutation Figure 6 . Correlation of brain CO activity with age and aggregate mtDNA mutational burden. (A) CO activity versus age. CO activity was measured in purified brain mitochondria from nine of the young control subject samples and 16 of the elderly subject samples (10 AD and six control) for which mutational burdens were determined. Values are normalized to CS activity to control for mitochondrial content of different samples. There is a negative correlation of CO activity with age (solid line, slope = -0.006, different from 0 at P = 0.0077; dotted lines, the 95% confidence interval on the slope). (B) CO activity versus mtDNA mutational burden. There is a negative correlation of CO activity with mtDNA mutational burden (solid line, slope = -0.108, different from 0 at P = 0.0256; dotted lines, the 95% confidence interval on the slope). burden of only 3 × 10 -6 /bp in a 100 bp region overlapping ND3. The cause for this 60-fold difference is not clear. However, their subjects were all in their fifties, younger than those studied here. Additionally, there were substantial differences in disease state, tissue examined (lung and colon), region of the genome and methodology used. Our estimate of 2 × 10 -4 /bp is of the same order of magnitude as the aggregate point mutation burden (4.8 × 10 -4 /bp, not counting the A3243G mutation) found in muscle from a single 24-year-old subject with MELAS (55). Kovalenko et al. (55) found no mutations in a 30-year-old control and hypothesized that the increased mutational burden in their MELAS case was due to oxidative stress from mitochondrial dysfunction. Therefore, the average aggregate burden of 2 × 10 -4 mutations/bp in normal aging is similar to a mutation level hypothesized to be due to pathologic mitochondrial dysfunction. It is also similar to the aggregate burden in the D-loop of two elderly subjects (3.5-9.0 × 10 -4 /base) (41). Jazin et al. (41) did not find any mutations outside the D-loop and hypothesized that coding regions might have less tolerance for mutations than non-coding regions. However, they examined only 5703 non-D-loop base pairs (23 clones) in only a single subject. Finally, the average aggregate point mutation burden of 2 × 10 -4 mutations/bp found by sequencing is consistent with the levels of individual tRNA point mutations (5-10 × 10 -4 ) determined by allele-specific PCR (18, 40) or double PCR with digestion (24) .
One feature of note in our study is that although the aggregate mutational burden was high, the majority of mutations found in brain were individually rare, found in at most one or occasionally two clones out of 24-96 examined. Thus, individual mutations are generally present at burdens much less than the minimum 50% threshold generally required before dysfunction is observed (17) . There were only seven examples of homoplasmic or high-level heteroplasmic mutations, which, because they were present in all clones from two widely separated brain regions, were likely to be inherited polymorphisms. This is somewhat different from the results of Michikawa et al. (43) in fibroblasts. They found several heteroplasmic mutations present at high levels, and these mutations were clearly acquired, as demonstrated by longitudinal study of several individuals. A potential explanation for this difference lies in the fact that neurons are post-mitotic, whereas fibroblasts continue to divide. Computer modeling shows that random mutation replication, and segregation of mtDNA will eventually give rise to a homoplasmic mutation after sufficiently many cell divisions (56, 57) . In settings such as a tumor or fibroblasts in culture, where clonal expansion of a cell with a particular homoplasmic mutation is possible, that mutation could become a high proportion of all the mtDNAs in the sample. In postmitotic cells, it may still be possible that mtDNA mutations become homoplasmic through repeated cycles of mitochondrial replication and turnover, even without cell division. However, without cell division, a mutation that becomes homoplasmic within a cell will remain confined to that single cell. In our analysis, each mtDNA sample likely came from at least several million different cells, and, except in the unlikely circumstance that the same mutation repeatedly occurred and became homoplasmic in multiple different neurons, a single mutation is unlikely to reach a high burden.
Thus, we have shown that the aggregate level of multiple distinct, individually rare point mutations is higher in brain mtDNA from elderly subjects than in brain mtDNA from younger controls. Moreover, this level is higher than expected from previous estimates. These findings significantly bolster the assertion that mitochondrial mutations accumulate with age and therefore support this aspect of the mitochondrial theory of aging.
However, the additional assertion that these mutations result in mitochondrial dysfunction and physiological decline requires more caution. On one hand, the aggregate burden of point mutations in elderly subjects is high, and a large proportion (60%) of these point mutations change an amino acid. If the mutational burden and frequency of amino acid change were similar in all coding genes, in principle a substantial fraction of respiratory enzyme complexes would bear at least one mutated subunit (Table 1) , though only a subset would alter evolutionarily conserved amino acids. Furthermore, mitochondrial reserve may be less than previously suspected, perhaps only 40% for CO (58, 59) . Thus, together with deletions and other rearrangements, un-repaired oxidative alterations, and multi-factorial other mtDNA lesions that would not be detected by our methodology, a high aggregate burden of point mutations might potentially alter mitochondrial function.
Indeed, we actually found that CO activity correlated negatively with age and increasing burden of mitochondrial mtDNA point mutations (Fig. 6) . Others have also found a decrease in CO activity in aging primate brain (60) . Of note, the 20% decrease in CO activity with aging is consistent with the 29% of CO complexes predicted to carry at least one mutant subunit ( Table 1) , considering that not all mutations are deleterious.
On the other hand, these data should be interpreted cautiously. The negative correlation of CO activity with increasing mtDNA mutational burden (Fig. 6B) is consistent with the mitochondrial mutations causing dysfunction, but other factors may also be operative. For example, Isobe et al. (61) suggest that nuclear mutations may play a role in the agerelated decrease in mitochondrial respiratory activity. Other aging-related factors, such as oxidative stress, might adversely affect both mutational burden and CO activity by independent mechanisms, and such factors may also play a role in explaining the correlation that both have with aging (Figs. 2B and 6A) and therefore with each other.
The autosomal dominant disorders affecting mtDNA stability provide a precedent for mitochondrial dysfunction due to multiple distinct, individually rare mutations (62) . In these disorders, multiple species of mtDNA deletions accumulate, each of which is individually rare, but which are associated with ragged red fibers and defects of respiratory chain enzyme activities. However, another point of caution is that mitochondria with multiple distinct mutations may in fact be able to complement each other, protecting the cell from mitochondrial dysfunction (63) . Also, multiple distinct, individually rare mutations are predicted to impair complex I preferentially, as suggested by Table 1 and previously discussed by Cortopassi and Wang (64) , but in AD, complex IV deficiency is the most consistently reported abnormality (6) (7) (8) .
Of note, we found no difference in aggregate mutational burden between AD and elderly control subjects, nor between areas of brain known to be hypo-or normo-metabolic AD. This is consistent with a prior functional study, in which AD and elderly control brain synaptosomal mtDNA was transferred into cybrids, and AD cybrids showed no functional deficits compared to elderly control cybrids (65) . However, it contrasts with other studies in which AD cybrids did show functional abnormalities (10, 11) . Thus, mtDNA mutations increase with age, but their significance in neurodegeneration remains uncertain.
In summary, this work is the first to quantify systematically the aggregate burden of point mutations in brain mtDNA from a large number of elderly control subjects, subjects with AD and younger control subjects. We found that, although the level of any one individual mutation is low, the aggregate burden of somatic mtDNA point mutations in aging and AD brain is high, and the accumulation of these mutations correlates negatively with CO activity. These results significantly bolster the mitochondrial theory of aging.
MATERIALS AND METHODS
Our strategy for detection of low-frequency mitochondrial mutations in brain involved five steps ( (Table 2 ). For the majority of AD and older control brains, two regions were obtained: primary occipital cortex, generally spared in AD, and temporoparietal or prefrontal polymodal association cortex, generally affected in AD (47) . Approval for using brain bank tissue was obtained from the Committee on Human Rights in Research of Weill Medical College of Cornell University/The New York Presbyterian Hospital.
Mitochondrial enrichment, DNA extraction and assessment of nuclear DNA contamination
In order to minimize contamination with nuclear pseudogenes, samples were enriched for mitochondria by differential centrifugation (66) prior to DNA extraction. Briefly, 0.1-1 g of brain tissue was homogenized in a motor-driven glass-Teflon homogenizer with five volumes of buffer A (10 mM Tris, 1 mM EDTA, 250 mM sucrose, 1 mM PMSF, pH 7.4). The homogenate was centrifuged at 1000 g for 10 min and the supernatant at 10 000 g for 10 min. The resulting pellet was resuspended in 1 ml buffer A, layered onto a 7.5-12% discontinuous gradient of Ficoll in buffer A, and centrifuged at 70 000 g for 24 min. DNA was then extracted from the pellet by standard SDS/proteinase K digestion, phenol-chloroform extraction, and ethanol-sodium-acetate precipitation (67) . Residual nuclear DNA contamination was assessed using yield of a 442 bp PCR product from the human histone H4 gene (GenBank accession no. X67081) as a marker for nuclear DNA. The primers were 5′-GTT CTC AAG GTG TTT CTG GA-3′ Table 1 . Expected fractions of mutant proteins and respiratory complexes with at least one mutant subunit a a Assumes that an aggregate point mutation burden of f = 2 × 10 -4 /base is similar throughout the genome, and that 60% of all point mutations result in an amino acid change. For a gene of length L, x = 1 -(1 -f) L and y = 0.6x. For a respiratory complex with n subunits, (nucleotides 434-453) and 5′-CTA CTC ATT TAT CGG ACT CG-3′ (nucleotides 875-856), and the thermocycling conditions were identical to those described for post-cloning PCR below. Purified mtDNA samples were used only if the histone PCR product was faint or absent, indicating a low degree of nuclear DNA contamination.
Pre-cloning PCR
We examined a 1197 bp fragment of the first subunit of CO (CO1), amplified using forward primer 5′-CTC GGA GCT GGT AAA AAG-3′ [L5818-5835, nucleotides numbered according to the Cambridge reference sequence (68, 69) ] and reverse primer 5′-ACG TGT CGT GTA GTA C-3′ (H7014-6999). CO1 is one of the longest mtDNA-encoded polypeptides (1542 bp), and thus may be one of the most vulnerable to random mutational hits. Additionally, CO1 primers were available that do not amplify nucleus-embedded pseudogenes, thereby avoiding a major potential source of artifact. Pre-cloning PCR was performed using the Expand High Fidelity PCR System (Roche Molecular Biochemicals) exactly as directed by the manufacturer. Fifteen nanograms of mtDNA was used as template in a 50 µl volume. Thermocycling was performed in a PCRExpress machine (Thermo-Hybaid, Franklin, MA). Thermocycling conditions were: 94°C for 2 min (one cycle); 94°C for 15 s, 57°C for 30 s, 72°C for 45 s (10 cycles, then an additional 5 s extension time/cycle for 17 cycles); 72°C for 3 min (one cycle). Unincorporated primers and dNTPs were removed using the Qiaquick PCR purification kit (Qiagen, Valencia, CA) as directed by the manufacturer.
Cloning
Individual molecules from the purified PCR product were then cloned into Escherichia coli using the TOPO TA cloning system (Invitrogen, Carlsbad, CA) with blue-white screening, as directed by the manufacturer. The assumption that each clone originates from an individual mtDNA molecule was verified by cloning a 1:1 mixture of PCR products known to differ at a polymorphic site, and only one in 64 colonies contained both products (data not shown).
Post-cloning PCR
For each sample that was cloned, 24-96 white or pale blue bacterial colonies were swiped with sterile pipette tips and scraped into 15 µl distilled water. The bacterial colonies then served as template to recover the cloned CO1 fragment by PCR, using the same primers (L5818-5835, H7014-6999) as the pre-cloning PCR. The post-cloning PCR was performed using the HotStarTaq DNA polymerase kit (Qiagen) as directed by the manufacturer. Thermocycling conditions were: 94°C for 15 min (one cycle); 94°C for 1 min, 50°C for 1 min, 72°C for 1 min (40 cycles); 72°C for 10 min (one cycle). Unincorporated primers and dNTPs were removed using the Qiaquick PCR purification kit (Qiagen) as directed by the manufacturer.
Sequencing
Purified products from the post-cloning PCR were sequenced using BigDye Terminator Cycle Sequencing chemistry (Applied Biosystems, Foster City, CA). The sequencing reaction contained 6 µl purified PCR product, 3 µl BigDye Ready Reaction mix and 1 µl primer (5′-AGT CCA ATG CTT CAC TC-3′, L5863-5879, final concentration 250 nM). Thermocycling conditions were: 94°C for 2 min (one cycle); 96°C for 10 s, 57°C for 5 s, 60°C for 4 min (25 cycles). Unincorporated primers and dye terminators were removed using Centri-Sep 96 gel filtration plates (Princeton Separations, Adelphia, NJ). Samples were then sequenced on an ABI Prism Number of occipital cortex samples 11 10 7 3700 DNA Analyzer (Applied Biosystems). The first 69 mutations found were also sequenced in reverse (primer 5′-AGA ATA TAA ACT TCA GGG TGA-3′, H6640-6620), and 66 were confirmed, giving an accuracy of 95%. Subsequent samples were sequenced with the forward primer only.
Data analysis
Sequences were edited using Factura 1.0 (Applied Biosystems) to remove ambiguous portions from the 5′ and 3′ ends. All sequences from clones of the same sample were aligned with the Cambridge reference sequence (GenBank accession no. J01415) using a clustal algorithm in Sequence Navigator 1.0 (Applied Biosystems). Sequences were generally read from nucleotide 5951 to 6560 (610 bases), although, depending on sequence quality, some were read starting from 5885 or ending at 6604. Bases within this range differing from the Cambridge reference sequence were flagged by an automated comparison routine and manually checked against the electropherogram. The mutational burden for a given sample was calculated as the number of mutations found divided by the total number of bases examined. Homoplasmic polymorphisms found in all clones of a sample were not counted in this analysis. Statistics were analyzed using Statview 5.0.1 (SAS Institute, Cary, NC).
Mathematical modeling of PCR error
Let f be the PCR polymerase error rate per base, L the length of the strand to be amplified, S 0 the initial number of strands and η the fraction of molecules replicated during each cycle. The probability of introducing k errors while copying a strand is The overall PCR error per base is then <k>/L = cfη/(1 + η).
Mitochondrial enzyme assays
Mitochondria were isolated from frozen brain tissue as described above, frozen at -80°C in 220 mM mannitol, 70 mM sucrose, 50 mM Tris-HCl, 1 mM EDTA (pH 7.4) and assayed within 7 days. CO and CS activities were measured as previously described by Bowling et al. (60) . Measurements were performed in triplicate on a single aliquot, unless there was only sufficient material for duplicate determinations. CO and CS measurements were made on the same aliquot in the same sitting (within 2 h), without an intervening freeze-thaw cycle.
